Amgen shares new Tavneos analysis in effort to resolve FDA dispute
Amgen shared a new analysis with the FDA that the company said supports keeping its controversial rare disease drug Tavneos on the market. The submission, made Thursday, includes an independent reevaluation ...
July 24, 2026 02:07 PM EDT PharmaFDA+ Amgen shares new analysis with FDA in bid to keep Tavneos on the market Nicole DeFeudis Senior Reporter Amgen shared a new analysis with the FDA that the company said supports keeping its controversial rare disease drug Tavneos on the market. The Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that